2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Azenosertib: new trials by email Literature Review of Azenosertib trials Research Report on Azenosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Azenosertib, Niraparib - Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 117 | 2022-01-27 | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma Azenosertib - Uterine Serous Carcinoma | Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 92 | 2021-07-28 | 2026-03-18 |
Cystadenocarcinoma, Serous (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (2)
United States (2) · Australia (1) · Canada (1) · France (1) · Georgia (1)